Skip to content

Prostamax

Khavinson bioregulator

Also: KEDP · Lys-Glu-Asp-Pro · H-Lys-Glu-Asp-Pro-OH · Prostomax · prostate tetrapeptide · Простамакс

CautionLibido & hormonesInjection

Khavinson's 'prostate' tetrapeptide KEDP; rat and cell work only, a handful of mixed user reports.

Safety tier
Caution
strict bar
Positive
50%
of 6 reports
Per month
≈ €27–110≈ $30–120
estimate
Rank
#18
of 86 research peptides

At a glance

Onset
The positive users noticed changes within 4-5 days of daily injections; another only near the end of a vial, after switching to intramuscular.
Lasts
Run as 10-30 day courses; one user's symptoms returned within weeks of stopping, another's were still gone two months on.
Access
Grey market
Best effects
Wider urine stream and less urgency in BPH (two first-hand reports) · less painful ejaculation and pelvic pain in chronic prostatitis (two first-hand reports) · claimed: anti-inflammatory and antioxidant effects in the prostate (patent rat data)
Downsides
No effect for some, even after a full vial · prostate pain (one report) · symptoms returned within weeks of stopping (one report) · users argue over subcutaneous versus intramuscular injection; neither has been studied in people
Typical use
No established human dose. Reddit users inject 0.5-5 mg a day subq or IM (one used 1.5 mg rectally) for 3-4 weeks, two or three times a year; vendor guides suggest as little as 300-500 mcg a day.
Stacked with
Stacked with
Libidon: The Khavinson sequence pairs a short synthetic peptide with the matching tissue extract afterwards: Prostamax for about 20 days, then the prostate extract capsules. · Vesilute or Chitomur: Added by men with urinary symptoms; one BPH user moved on to Vesilute injections after Prostamax. · Vesugen: Often bought together in Khavinson 'men's health' orders; no reports of the combination.

Safety

Watch
A PSA rise to about 15 on Prostamax that stayed near 13 six weeks after stopping (one user, who also has BPH); whatever the cause, a peptide that may change PSA can muddy prostate-cancer screening · In lymphocytes from elderly donors it doubled sister-chromatid exchanges, read by its authors as chromatin loosening; the same marker is used to screen for DNA damage. Single-group in-vitro finding · Grey-market injectable vials: purity, sterility and identity unverified; FDA named a US seller's Prostamax an unapproved new drug in June 2026
Tier by safety barStrict CautionBalanced CautionEvidence only Caution
  • Seen harm1 of 3
  • Mechanism1 of 3
  • Data gap3 of 3
  • Silent harm2 of 3
  • Product3 of 3
Never if
Prostate cancer, or a raised or rising PSA not yet investigated · Men replacing assessment and treatment of urinary symptoms (alpha-blockers, 5-alpha-reductase inhibitors) with it · Pregnancy or breastfeeding (no human reproductive data)
Why each score
Seen harm 1/3
No study reports adverse events, and there is no case report. Two first-hand Reddit reports are isolated and confounded: one user had 'tremendous prostate pain' of unstated duration, and one with BPH saw his PSA rise to about 15 while on it, still 13 six weeks after stopping, which may equally reflect an underlying prostate condition. r/Prostatitis: prostate pain on Prostamaxr/Prostatitis: PSA rose while on Prostamax, still high six weeks after stopping
Mechanism 1/3
No named pathway to serious harm has been shown. The signals are single-group and in vitro or ex vivo: Prostamax stimulated growth of rat prostate explants, and doubled sister-chromatid exchanges in elderly donors' lymphocytes (read by its authors as chromatin loosening, though the marker is also used to screen for genotoxicity); in rats with induced BPH it shrank rather than enlarged the gland. Speculative, so 1. Zakutskii et al. 2006: prostate explant growth stimulated by Prostamax (PubMed 17152728)Dzhokhadze et al. 2012: sister-chromatid exchanges doubled in lymphocytes (PubMed 23221144)KEDP in a rat model of benign prostatic hyperplasia (Modern Research in Inflammation, 2014)
Data gap 3/3
Registered nowhere as a drug or supplement, and no peer-reviewed human safety data for KEDP: the only patient figures (35 with chronic prostatitis, 19 with BPH) are unrandomised examples in the developers' 2001 patent, never published. Published work is cell, organ-culture and rat studies. RU 2177802 C1: Tetrapeptide regulating prostate functionPeptx: Prostamax (KEDP), what the research actually shows
Silent harm 2/3
With no credible mechanism, rated on the harm actually reported: a PSA rise, silent without a blood test and able to confuse prostate-cancer screening, alongside injection-site reactions and prostate pain that are felt at once. r/Prostatitis: PSA rose while on Prostamax
Product 3/3
Only sold as grey-market 20 mg vials (and prefilled pens) for subcutaneous or intramuscular injection, of unverified purity and sterility; there is no regulated or capsule form. FDA named one US seller's Prostamax an unapproved new drug in June 2026, citing the risks of injectables. FDA warning letter to Wholesale Peptide, 17 June 2026Mendias & Awan 2026 preprint: 6,441 grey-market peptide samples, 42-71% failed quality criteria, 15% had endotoxin

User reports

All 7 reports
Users report
Few reports, and they disagree. Five first-hand Reddit accounts, almost all from men with BPH or chronic prostatitis. One injecting 5 mg a day says his urinary stream widened within five days and that inflammation, urinary symptoms and painful ejaculation were still gone two months on, though the prostate did not shrink; another, using it rectally, reports 95% less ejaculation pain and stronger morning erections by day four. Against that, one felt nothing on 1 mg a day, one had 'tremendous prostate pain', and one who first credited it (only once he switched to intramuscular) later called it a bust and saw his PSA climb to about 15 while on it, still 13 six weeks after stopping. On X a man with prostate cancer credits it, alongside leuprolide, with shrinking his prostate, and a promoter selling it with a discount code describes his own BPH relief. Felt nothing: 1 of 5 first-hand Reddit reports; too few to judge.
Glowing 1Positive 2Mixed 1Nothing 1Bad reaction 1
  • r/Prostatitis

    I recently started taking Prostamax peptide injections at 5 milligrams once a day. Within about 5 days my urinary stream got wider and almost all of my inflammation has disappeared.

    • 16 points
    Glowing5 mg once a dayInjectionplanned one month; symptoms still gone at two months
  • @mcf_4766

    I'm taking peptides For prostate cancer PROSTAMAX PNC127 LUPRIDE THYMULIN shrunk the prostrate from 49mm to 28mm don't go to the bathroom 4 times a night but I still have 2 lesions from the last MRI 10 and 14mm .

    • 3 likes
    Positive
  • r/Prostatitis

    It created tremendous prostate pain for me…

    • 2 points
    Bad reaction

Studies

Evidence
Animal only — No published human study. Peer-reviewed work is cell and chromatin studies in lymphocytes from elderly donors (one Tbilisi group), one rat prostate organ-culture report, and two rat models in a low-tier open-access journal (sulpiride-induced BPH and chronic aseptic prostatitis). The developers' 2001 patent describes 35 chronic-prostatitis and 19 BPH patients against conventional treatment, unrandomised and never published.
Caveat
Evidence that Prostamax does anything for the prostate in people is absent: the prostate label comes from the developers' own patent, the published rat work is in a low-tier journal, and the chromatin studies used blood cells. The patent's effective rat dose was 0.1 mcg a day, while users inject 0.5-5 mg, thousands of times more, with no rationale. No tumour data exist either way, so men with prostate cancer, or a rising PSA, are using it blind.
4 more studies and 4 sources

Sources

Similar peptides

Research notes, not medical advice. Updated . Also as Markdown.

Sequence

The peptide's chain of amino acids from its start (the N-terminus) to its end, one bead and one letter for each: A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H histidine, I isoleucine, K lysine, L leucine, M methionine, N asparagine, P proline, Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine. A modification such as an N-acetyl cap or a C-terminal amide changes how long it lasts in the body. Length tells related peptides apart, from a two-residue dipeptide like carnosine to a 43-residue protein like thymosin beta-4, and predicts neither effect nor safety.

Report grades

Every first-hand Reddit or X report is graded on its own, from glowing through positive, mixed, nothing and negative to bad reaction, and the bar shows how those grades split. Posts that look vendor-adjacent stay on the peptide's page but are left out of the counts.

GlowingPositiveMixedNothingNegativeBad reaction

% positive

The share of a peptide's graded Reddit and X reports that are glowing or positive, vendor-adjacent posts left out. A peptide with few reports is pulled toward the average of all reports, as if it had eight average ones besides its own, so two glowing posts cannot top the list. Peptides rank by this figure, those with no graded report yet after those with one, and Avoid ones after every other entry.

Researcher estimate

No first-hand report of this peptide has been graded yet, so the figure is the researchers' own rating out of 10 from what they read about it. It ranks after every peptide with graded reports until its own arrive.

Safety tier

Each peptide is tiered Clean, Caution or Avoid from its five risk axes under the chosen safety bar. An Avoid peptide carries a real risk of harm, a plausible route to serious harm rather than mere unpleasantness, so it stays listed with the reason but ranks behind every other entry, however good its reviews.

Safety bar

The safety bar sets how much risk it takes to rate a peptide Avoid. Strict: out on any serious mechanism with little human data, or any documented serious harm. Balanced: out on documented serious harm (unless it is obvious, reversible and from a regulated product), or a serious mechanism whose harm would be silent with no human data at all. Evidence only: out only on documented serious harm in humans that is lasting, delayed or from grey-market product.

Seen harm

Documented serious adverse events in humans, from 0 for none despite real exposure to 3 for deaths or several well-documented serious harms. Serious means a hospital or emergency visit or harm lasting weeks, so a headache or a bad night does not count.

Mechanism

A plausible biological route to serious harm at the doses people use, such as growth-factor signalling, hormone-axis suppression, heart or blood-pressure effects or immune activation. It runs from 0 when none is known to 3 when a dangerous pathway has been shown in living animals.

Data gap

How little human safety data exists for the molecule actually sold, from 0 for an approved drug with large trials and years of use to 3 for no human safety data at all. A modified analogue does not inherit its parent's trials.

Silent harm

Whether the feared harm would show quickly or stay hidden, from 0 when it is obvious and goes on stopping to 3 when it is silent and delayed, like tumour promotion or slow organ damage. User reports cannot reveal a harm that takes years to appear, so a high score here limits what good reviews can tell you.

Product

The risk of what people actually buy, from 0 for a regulated pharmacy or supplement product taken by mouth or on the skin to 3 for a grey-market injectable. In one dataset of 6,441 grey-market samples, 42–71% failed basic quality criteria and 15% carried endotoxin; taken by mouth or in the nose, a pack avoids the injection risks.

Evidence

The strongest kind of study behind the peptide's effects, from an approved drug through human controlled trials and small human studies to animal work or nothing of its own. Animal results often fail to carry over to people.

Access

How people get it: as an approved drug, a compounded prescription, an over-the-counter supplement or from the grey market, where nobody checks the vial. The channel decides both the legal position and the risk of a bad batch.

Price per month

Thirty days of the typical dose, from its low end to its high end, priced at the listing a careful buyer would choose: in stock, from a shop scoring 4 of 5 on trust (third-party tested where no score is set), failing that 3, a pure pack before a blend, a European shop first, then the cheapest per mg. The range is the dose's, not the shops'. A per-dose amount counts once a day unless the dose says otherwise. The shop table keeps each listing's price per mg, per gram for bulk supplements. Where no listing can be priced the researchers' own estimate stands in, and says so.

Dose users report

The middle half of the daily doses stated in at least five first-hand reports, vendor posts left out. Where its middle sits more than twice above or below the declared dose, the month is priced at it as well, since what people take is what they pay for.

Shop trust

Each shop's trust on a 1–5 scale, read from its testing and its reputation: 1 for serious red flags (fabricated COAs, scam reports, impersonation, a closed shop), 2 for no public testing, a new shop or active complaints such as seized parcels, 3 for its own COAs or a short track record, 4 for verified third-party testing or a strong reputation, and 5 for third-party batch reports that name the shop, with years of good independent reputation. A shop without a score counts third-party batch testing as 4, its own COAs as 3 and no public tests as 2.

Best value

Within a category or a goal, a peptide that no other beats on both counts: none is rated more positively for the same or a lower monthly price, and none costs less for the same or a higher rating. The chart joins these into the best-value line; the cheapest of them and the best-rated of them both make it, so the line spans the trade-off from cheap to best. Avoid entries never count, and a peptide needs both a % positive and a price to be compared.

Testing

Whether the shop publishes lab results: third-party tested means an independent lab checks each batch, own COA means the shop's own certificate of analysis, and no public tests means neither. A certificate shows purity, not safety.

Added peptide

Some packs sold under one peptide's name hold a second one, such as 5 mg GHK-Cu in a nasal kit, stated only in the description. Sprayed in the nose or injected it reaches the blood like an injection, so it carries the risk of that route and is tiered as the injectable form, whatever its tier on the skin. A pack whose page gives no contents list may hold more than its name.